18F-DCFPyL PET/CT 在前列腺癌根治性治疗后 PSA≤0.2 ng/mL 患者中的诊断效能
本回顾性研究纳入 93 例根治性治疗后 PSA≤0.2 ng/mL 的前列腺癌患者,共 96 次 18F-DCFPyL PET/CT,以随访和/或活检为金标准。PSA≤0.1 ng/mL 组检出率 58.7%(27/46),0.2 ng/mL 组 44%(22/50),两组灵敏度均为 100%,阴性预测值均为 100%。作者认为该检查对初诊 GS≥8 及仅接受 ADT 或 ADT 加化疗者最有帮助。
要点
- PSA≤0.1 ng/mL 组检出率 58.7%(27/46),0.2 ng/mL 组 44%(22/50)。
- 两组灵敏度均为 100%,阴性预测值均为 100%。
- 初诊 GS 8–10、M1、精囊侵犯等与 PET/CT 阳性显著相关(P<0.05)。
核心结论
- 根治性治疗后低 PSA 水平的前列腺癌患者中,18F-DCFPyL PET/CT 对初诊 GS≥8 者及仅有 ADT 或 ADT 加化疗史者最有帮助。
- 18F-DCFPyL PET/CT 具有极好的阴性预测值。
- 原文指出该检查无 PSA 阈值指征,且 PSA 水平与阳性病灶 SUVmax 无相关性。
研究设计与样本
- 回顾性研究,纳入根治性治疗后 PSA≤0.2 ng/mL 且行 18F-DCFPyL PET/CT 的前列腺癌患者。
- PET/CT 需在 PSA 检查 1 周内完成,且期间无治疗改变、无其他癌症史。
- 纳入随访至少 6 个月(中位 11 个月,范围 6–21 个月)或有疑似病灶 definitive 活检结果者。
- 共 93 例患者的 96 次 18F-DCFPyL PET/CT 符合纳入标准。
主要发现
- 阳性组中位 Gleason 评分 8(范围 6–10),阴性组 7(范围 6–10)。
- 阳性组中位年龄 71 岁(范围 50–90),阴性组 69 岁(范围 45–88)。
- 49 次(51%)PET/CT 阳性,47 次(49%)阴性。
- 阳性病灶部位包括前列腺床、盆腔淋巴结、骨、胸部及锁骨上淋巴结、肺和肾上腺。
- 阳性病灶 SUVmax 范围 1.9–141.4,最小阳性淋巴结为 0.4 cm。
关键数值与推荐
- PSA≤0.1 ng/mL 组基于 scan 的灵敏度 100%、特异度 95%、阳性预测值 96%、阴性预测值 100%。
- PSA 0.2 ng/mL 组基于 scan 的灵敏度 100%、特异度 97%、阳性预测值 95%、阴性预测值 100%。
- 初诊 GS 8–10、已知转移状态(M1)、前列腺外侵犯、精囊侵犯及极高危前列腺癌与阳性 PET/CT 结果显著相关(P<0.05)。
- 根治性前列腺切除术(伴或不伴盆腔淋巴结清扫)与阴性 PET/CT 结果强相关(P<0.001)。
- 仅接受 ADT 或 ADT 加化疗者 PET/CT 结果最可能为阳性(P=0.026)。
临床怎么用
- 作者认为,根治性治疗后低 PSA 水平患者中,18F-DCFPyL PET/CT 对初诊 GS≥8 者及仅有 ADT 或 ADT 加化疗史者最有帮助。
- 作者指出该检查具有极好的阴性预测值。
- 作者指出无 PSA 阈值用于 18F-DCFPyL PET/CT 指征,且 PSA 水平与阳性病灶 SUVmax 无相关性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the role of 18 F-DCFPyL PET/CT in the evaluation of prostate cancer (PC) patients after definitive treatment and with low-level prostate-specific antigen (PSA) level of ≤0.2 ng/mL. PATIENTS AND METHODS: This retrospective study was conducted in PC patients who received definitive treatments with PSA level of ≤0.2 ng/mL and underwent 18 F-DCFPyL PET/CT within a 1-week interval of PSA examination, and without interval treatment change or history of other cancer. Patient and tumor characteristics at initial diagnosis, treatment regimens, and findings on 18 F-DCFPyL PET/CT were collected. Patients with minimal 6-month (median, 11 months; range, 6-21 months) follow-up or definitive biopsy results of the suspected PET/CT findings were included. Imagine findings were reached with consensus among experienced board-certified nuclear medicine physicians. Comprehensive follow-up and/or biopsy results were used as definitive determination of presence or absence of disease. Comparisons between groups of positive and negative 18 F-DCFPyL PET/CT were done by using descriptive statistics. RESULTS: A total of 96 18 F-DCFPyL PET/CTs from 93 patients met the inclusion criteria. The median Gleason score (GS) of positive group is 8 (range, 6-10), whereas negative group is 7 (range, 6-10). The median age of positive group is 71 (range, 50-90), whereas negative group is 69 (range, 45-88). There were 49 positive (51%) and 47 negative 18 F-DCFPyL PET/CTs (49%). Detection rates at PSA level of ≤0.1 and 0.2 ng/mL were 58.7% (27/46) and 44% (22/50), respectively. The scan-based sensitivity, specificity, positive predictive value, and negative predictive value are 100%, 95%, 96%, and 100% in group with PSA level of ≤0.1 ng/mL, and 100%, 97%, 95%, and 100% in group with PSA level of 0.2 ng/mL, respectively. Sites of involvement on positive 18 F-DCFPyL PET/CTs were prostate bed, pelvic lymph nodes, bone, chest and supraclavicular lymph nodes, lung, and adrenal glands. The SUV max value on positive lesions ranged from 1.9 to 141.4; the smallest positive lymph node was 0.4 cm. High GS of 8-10, known metastatic status (M1), presence of extraprostatic extension, presence of seminal vesicle invasion, and very high-risk PC are significantly associated with positive 18 F-DCFPyL PET/CT results ( P < 0.05). Of all analyzed treatment regimes, upfront surgery (radical prostatectomy with or without pelvic lymph node dissection) had strong correlation with negative PET/CT results ( P < 0.001). If patients received ADT only, or ADT plus chemotherapy, the PET/CT results were most likely positive ( P = 0.026). For other treatment regimes, there were no statistical differences between the groups ( P > 0.05). CONCLUSIONS: In the presence of low PSA level in PC patients after definitive treatment, 18 F-DCFPyL PET/CT is most beneficial in detection of disease in patients with GS of 8 or higher at the time of diagnosis, and the ones who have history of ADT only, or ADT plus chemotherapy. There is excellent negative prediction value of 18 F-DCFPyL PET/CT. However, there is no cutoff PSA level for 18 F-DCFPyL PET/CT indication and no correlation between PSA level and SUV max of positive lesions on 18 F-DCFPyL PET/CT.
引用
- Lu Y, Wilson ZJ, Xu G, et al. Diagnostic Performance of PSMA-Based 18 F-DCFPyL PET/CT in Prostate Cancer Patients After Definitive Treatment With PSA Level ≤0.2 ng/mL. Clin Nucl Med. 2023. PMID: 37801580. doi:10.1097/RLU.0000000000004893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。